Abstract：
UNASSIGNED: As government agencies around the globe contemplate approval of the first psychedelic medicines, many questions remain about their ethical integration into mainstream medical practice.
UNASSIGNED: To identify key ethics and policy issues related to the eventual integration of psychedelic therapies into clinical practice.
UNASSIGNED: From June 9 to 12, 2023, 27 individuals representing the perspectives of clinicians, researchers, Indigenous groups, industry, philanthropy, veterans, retreat facilitators, training programs, and bioethicists convened at the Banbury Center at Cold Spring Harbor Laboratory. Prior to the meeting, attendees submitted key ethics and policy issues for psychedelic medicine. Responses were categorized into 6 broad topics: research ethics issues; managing expectations and informed consent; therapeutic ethics; training, education, and licensure of practitioners; equity and access; and appropriate role of gatekeeping. Attendees with relevant expertise presented on each topic, followed by group discussion. Meeting organizers (A.L.M., I.G.C., D.S.) drafted a summary of the discussion and recommendations, noting points of consensus and disagreement, which were discussed and revised as a group.
UNASSIGNED: This consensus statement reports 20 points of consensus across 5 ethical issues (reparations and reciprocity, equity, and respect; informed consent; professional boundaries and physical touch; personal experience; and gatekeeping), with corresponding relevant actors who will be responsible for implementation. Areas for further research and deliberation are also identified.
UNASSIGNED: This consensus statement focuses on the future of government-approved medical use of psychedelic medicines in the US and abroad. This is an incredibly exciting and hopeful moment, but it is critical that policymakers take seriously the challenges ahead.
UNASSIGNED: To identify key ethics and policy issues related to the eventual integration of psychedelic therapies into clinical practice.
UNASSIGNED: From June 9 to 12, 2023, 27 individuals representing the perspectives of clinicians, researchers, Indigenous groups, industry, philanthropy, veterans, retreat facilitators, training programs, and bioethicists convened at the Banbury Center at Cold Spring Harbor Laboratory. Prior to the meeting, attendees submitted key ethics and policy issues for psychedelic medicine. Responses were categorized into 6 broad topics: research ethics issues; managing expectations and informed consent; therapeutic ethics; training, education, and licensure of practitioners; equity and access; and appropriate role of gatekeeping. Attendees with relevant expertise presented on each topic, followed by group discussion. Meeting organizers (A.L.M., I.G.C., D.S.) drafted a summary of the discussion and recommendations, noting points of consensus and disagreement, which were discussed and revised as a group.
UNASSIGNED: This consensus statement reports 20 points of consensus across 5 ethical issues (reparations and reciprocity, equity, and respect; informed consent; professional boundaries and physical touch; personal experience; and gatekeeping), with corresponding relevant actors who will be responsible for implementation. Areas for further research and deliberation are also identified.
UNASSIGNED: This consensus statement focuses on the future of government-approved medical use of psychedelic medicines in the US and abroad. This is an incredibly exciting and hopeful moment, but it is critical that policymakers take seriously the challenges ahead.
摘要：
随着全球政府机构考虑批准第一批迷幻药物，关于他们融入主流医疗实践的伦理问题仍然存在许多问题。
■确定与迷幻疗法最终融入临床实践相关的关键伦理和政策问题。
■从2023年6月9日至12日，代表临床医生观点的27个人，研究人员,土著群体,工业,慈善事业,退伍军人,撤退促进者，培训计划,和生物伦理学家在冷泉港实验室的班伯里中心召集。在会议之前,与会者提交了迷幻药的关键伦理和政策问题。反应分为6大主题：研究伦理问题;管理期望和知情同意;治疗伦理;培训，教育,和从业人员的执照；公平和准入；以及把关的适当作用。在每个主题上都有相关专业知识的与会者，接下来是小组讨论。会议组织者（A.L.M.，I.G.C.,D.S.)起草了讨论和建议的摘要，注意到共识和分歧，作为一个小组进行了讨论和修订。
■这份共识声明报告了关于5个道德问题(赔偿和互惠，股本，和尊重；知情同意；专业界限和身体接触；个人经验；和把关)，由相应的相关行为者负责实施。还确定了进一步研究和审议的领域。
■这份共识声明的重点是美国和国外政府批准的迷幻药的未来医疗用途。这是一个令人难以置信的激动人心和充满希望的时刻，但至关重要的是，政策制定者必须认真对待未来的挑战。
■确定与迷幻疗法最终融入临床实践相关的关键伦理和政策问题。
■从2023年6月9日至12日，代表临床医生观点的27个人，研究人员,土著群体,工业,慈善事业,退伍军人,撤退促进者，培训计划,和生物伦理学家在冷泉港实验室的班伯里中心召集。在会议之前,与会者提交了迷幻药的关键伦理和政策问题。反应分为6大主题：研究伦理问题;管理期望和知情同意;治疗伦理;培训，教育,和从业人员的执照；公平和准入；以及把关的适当作用。在每个主题上都有相关专业知识的与会者，接下来是小组讨论。会议组织者（A.L.M.，I.G.C.,D.S.)起草了讨论和建议的摘要，注意到共识和分歧，作为一个小组进行了讨论和修订。
■这份共识声明报告了关于5个道德问题(赔偿和互惠，股本，和尊重；知情同意；专业界限和身体接触；个人经验；和把关)，由相应的相关行为者负责实施。还确定了进一步研究和审议的领域。
■这份共识声明的重点是美国和国外政府批准的迷幻药的未来医疗用途。这是一个令人难以置信的激动人心和充满希望的时刻，但至关重要的是，政策制定者必须认真对待未来的挑战。
